Publication | Closed Access

Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

InflammationThrombosisImmunohematologyHemostatic PotencyHematologyImmunologyHemophilia A ModelHemostasisRoutine SupplementationCoagulopathyBleeding DisorderImmunotherapyMedicineHealth Sciences